Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial-Reference-Cited by-同舟云学术

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

Published:2010-09 Issue:9 Volume:11 Page:845-852
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Masi Gianluca,Loupakis Fotios,Salvatore Lisa,Fornaro Lorenzo,Cremolini Chiara,Cupini Samanta,Ciarlo Andrea,Del Monte Francesca,Cortesi Enrico,Amoroso Domenico,Granetto Cristina,Fontanini Gabriella,Sensi Elisa,Lupi Cristiana,Andreuccetti Michele,Falcone Alfredo

Publisher

Elsevier BV

Subject

Oncology

Reference40 articles.

1. Cancer statistics, 2009;Jemal;CA Cancer J Clin,2009

2. Estimates of cancer incidence and mortality in Europe in 2008;Ferlay;Eur J Cancer,2010

3. First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first?;Loupakis;Curr Opin Oncol,2008

4. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy;Kopetz;J Clin Oncol,2009

5. Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials;O'Neil;Oncologist,2008

Cited by 223 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Carrier-free nano-prodrugs for minimally invasive cancer therapy;Nanoscale;2024

2. Colon Cancer;Tata Memorial Centre Textbook of Oncology;2024

3. Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial;British Journal of Cancer;2023-11-23

4. BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of Resistance: A Review of the Literature;Cancers;2023-10-31

5. Redefining the Incidence and Profile of Fluoropyrimidine-Associated Cardiotoxicity in Cancer Patients: A Systematic Review and Meta-Analysis;Pharmaceuticals;2023-03-30